Close Menu

NEW YORK (GenomeWeb) – Korean diagnostics firm NGeneBio said this week that it recently closed an $11 million Series B financing.

The company also achieved a CE-IVD mark for its HEMEaccuTest, which targets hematological malignancies, according to YoungJoon Moon, director of business development for the Seoul-based company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Feb
23
Sponsored by
Thermo Fisher Scientific

As the world continues to contend with coronavirus and a surge in the infection rate, labs are required to run more samples than ever before. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints.